Circulating enterolactone and risk of breast cancer: a prospective study in New York

2004

Circulating Enterolactone and Breast Cancer Risk

Sample size: 417 publication 10 minutes Evidence: moderate

Author Information

Author(s): Zeleniuch-Jacquotte A, Adlercreutz H, Shore R E, Koenig K L, Kato I, Arslan A A, Toniolo P

Primary Institution: New York University School of Medicine

Hypothesis

Does circulating enterolactone levels affect the risk of breast cancer?

Conclusion

The study found no inverse association between serum levels of enterolactone and breast cancer risk.

Supporting Evidence

Serum enterolactone levels were higher in breast cancer cases compared to controls.
The study had 80% power to detect a significant odds ratio.
Enterolactone was measured using a time-resolved fluoroimmunoassay.
Only incident cases of invasive breast cancer were included in the analysis.
Controls were matched based on menopausal status and age.
Antibiotic use was a significant exclusion criterion for participants.
Statistical analyses were performed using conditional logistic regression.

Takeaway

This study looked at whether a substance called enterolactone in the blood can help prevent breast cancer, but it didn't find any evidence that it does.

Methodology

The study used a nested case-control design within the NYU Women's Health Study, analyzing serum enterolactone levels in relation to breast cancer risk.